Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial.
Chinese medicine JCM-16021
Diarrhea-predominant
Irritable bowel syndrome
Randomized controlled trial
Treatment
Journal
Chinese medicine
ISSN: 1749-8546
Titre abrégé: Chin Med
Pays: England
ID NLM: 101265109
Informations de publication
Date de publication:
13 Nov 2021
13 Nov 2021
Historique:
received:
07
10
2021
accepted:
31
10
2021
entrez:
14
11
2021
pubmed:
15
11
2021
medline:
15
11
2021
Statut:
epublish
Résumé
Irritable bowel syndrome (IBS) is a common gastrointestinal functional disease. Adults with IBS may experience abdominal pain, change of bowel habits, and abnormal stool form without organic disease. IBS can seriously affect their work productivity and quality of life, especially diarrhea-predominant irritable bowel syndrome (IBS-D). The Chinese medicine JCM-16021 has been shown to be potentially effective in improving the symptoms of IBS-D based on a small scale clinical trial. Hence, a large scale clinical study is designed to further evaluate the efficacy and safety of the Chinese medicine JCM-16021 for IBS-D with traditional Chinese medicine (TCM) pattern of Liver Stagnation and Spleen Deficiency (LSSD). This study is a multi-center, randomized, double-blind, placebo-controlled clinical trial. 392 eligible participants will be enrolled with 2-week run-in, 8-week treatment and 8-week follow-up. After run-in period, participants will be randomized to receive either the Chinese medicine JCM-16021 or placebo for 8 weeks, and will have post-treatment follow up for another 8 weeks. The primary outcome is the improvement rate on the global assessment of improvement (GAI) at week 10. The secondary outcomes consist of changes of IBS-D symptoms, TCM pattern improvement, IBS-Quality of Life (IBS-QoL), IBS-Symptom Severity Score (IBS-SSS), safety, etc. RESULTS: A standard protocol has been developed for the study. The protocol will provided a detailed procedure to conduct a clinical trial and verify if the Chinese medicine JCM-16021 would significantly improve the overall symptoms of IBS-D with LSSD pattern of TCM by relieving abdominal pain, reducing stool frequency, improving the stool consistency and improving quality of life. The consolidated evidence from the study can shed light on the treatment of IBS-D with Chinese medicine. The protocol will provide details for investigators about the study following SPIRIT Statement. High-quality evidence on the efficacy and safety of Chinese medicine JCM-16021 for IBS-D will be provided through strict compliance with the protocol. ClinicalTrial.gov identifier: NCT03457324. Registered 8 February 2018, https://clinicaltrials.gov/ct2/show/NCT03457324?term=NCT03457324&draw=2&rank=1.
Sections du résumé
BACKGROUND
BACKGROUND
Irritable bowel syndrome (IBS) is a common gastrointestinal functional disease. Adults with IBS may experience abdominal pain, change of bowel habits, and abnormal stool form without organic disease. IBS can seriously affect their work productivity and quality of life, especially diarrhea-predominant irritable bowel syndrome (IBS-D). The Chinese medicine JCM-16021 has been shown to be potentially effective in improving the symptoms of IBS-D based on a small scale clinical trial. Hence, a large scale clinical study is designed to further evaluate the efficacy and safety of the Chinese medicine JCM-16021 for IBS-D with traditional Chinese medicine (TCM) pattern of Liver Stagnation and Spleen Deficiency (LSSD).
METHODS
METHODS
This study is a multi-center, randomized, double-blind, placebo-controlled clinical trial. 392 eligible participants will be enrolled with 2-week run-in, 8-week treatment and 8-week follow-up. After run-in period, participants will be randomized to receive either the Chinese medicine JCM-16021 or placebo for 8 weeks, and will have post-treatment follow up for another 8 weeks. The primary outcome is the improvement rate on the global assessment of improvement (GAI) at week 10. The secondary outcomes consist of changes of IBS-D symptoms, TCM pattern improvement, IBS-Quality of Life (IBS-QoL), IBS-Symptom Severity Score (IBS-SSS), safety, etc. RESULTS: A standard protocol has been developed for the study. The protocol will provided a detailed procedure to conduct a clinical trial and verify if the Chinese medicine JCM-16021 would significantly improve the overall symptoms of IBS-D with LSSD pattern of TCM by relieving abdominal pain, reducing stool frequency, improving the stool consistency and improving quality of life. The consolidated evidence from the study can shed light on the treatment of IBS-D with Chinese medicine.
CONCLUSION
CONCLUSIONS
The protocol will provide details for investigators about the study following SPIRIT Statement. High-quality evidence on the efficacy and safety of Chinese medicine JCM-16021 for IBS-D will be provided through strict compliance with the protocol.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrial.gov identifier: NCT03457324. Registered 8 February 2018, https://clinicaltrials.gov/ct2/show/NCT03457324?term=NCT03457324&draw=2&rank=1.
Identifiants
pubmed: 34774080
doi: 10.1186/s13020-021-00530-2
pii: 10.1186/s13020-021-00530-2
pmc: PMC8590321
doi:
Banques de données
ClinicalTrials.gov
['NCT03457324']
Types de publication
Journal Article
Langues
eng
Pagination
117Subventions
Organisme : The Innovative Technology Commission of HKSAR, China
ID : ITS-148-14FP
Informations de copyright
© 2021. The Author(s).
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Lancet Gastroenterol Hepatol. 2016 Oct;1(2):133-146
pubmed: 28404070
Gastroenterology. 2016 May;150(6):1469-1480.e1
pubmed: 27147123
Evid Based Complement Alternat Med. 2016;2016:4071260
pubmed: 27547226
Gastroenterology. 2020 Apr;158(5):1262-1273.e3
pubmed: 31917991
Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4
pubmed: 22426087
Lancet. 2020 Nov 21;396(10263):1675-1688
pubmed: 33049223
Am J Gastroenterol. 2017 Jun;112(6):892-899
pubmed: 28094313
Curr Pharm Des. 2017;23(34):5163-5172
pubmed: 28828984
Minerva Gastroenterol Dietol. 2017 Dec;63(4):355-372
pubmed: 27849120
JAMA. 2015 Mar 3;313(9):949-58
pubmed: 25734736
N Engl J Med. 2016 Jan 21;374(3):242-53
pubmed: 26789872
N Engl J Med. 2017 Jun 29;376(26):2566-2578
pubmed: 28657875
Am J Chin Med. 2015;43(3):385-406
pubmed: 25916468
Ann Intern Med. 2017 Jun 27;167(2):112-121
pubmed: 28654980
Evid Based Complement Alternat Med. 2012;2012:239638
pubmed: 22719782
World J Gastroenterol. 2010 Feb 21;16(7):837-45
pubmed: 20143462
Chin J Integr Med. 2019 Jan;25(1):71-79
pubmed: 30484022
J Gastroenterol Hepatol. 2007 Jan;22(1):143-4
pubmed: 17201902
World J Gastroenterol. 2014 Jan 14;20(2):384-400
pubmed: 24574708
J Gastroenterol Hepatol. 2002 Nov;17(11):1180-6
pubmed: 12453277
Infect Dis Clin North Am. 2010 Dec;24(4):961-75, ix
pubmed: 20937460
Dig Dis Sci. 1998 Feb;43(2):400-11
pubmed: 9512138
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):497-505
pubmed: 24751910
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917
pubmed: 32702295
Gastroenterology. 2020 Feb;158(3):786-788.e1
pubmed: 31711922
World J Gastroenterol. 2016 Feb 21;22(7):2219-41
pubmed: 26900286
Dig Dis Sci. 2003 Jul;48(7):1317-23
pubmed: 12870789
N Engl J Med. 2013 Feb 7;368(6):578
pubmed: 23388019
Aliment Pharmacol Ther. 2003 Sep 15;18(6):569-80
pubmed: 12969083
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Aliment Pharmacol Ther. 1997 Apr;11(2):395-402
pubmed: 9146781
Am J Chin Med. 2015;43(1):1-23
pubmed: 25579759
Gastroenterology. 2016 Feb 18;:
pubmed: 27144627